《大行報告》美銀證券下調創科(00669.HK)目標價至91.5元 重申「買入」評級
美銀證券發表報告指,近日到訪創科(00669.HK)客戶家得寶(HD.US)店舖後,認為在外在環境不利,包括利率、樓宇銷售及消費等因素影響下,創科推出新產品的策略,長遠而言可以提供更強市場定位,公司投資發展不同類別的產品,例如戶外工具、清潔工具、手提管道工具等,亦有一定發展空間。
創科旗下電動工具品牌Milwaukee早前下調增長預測,雖然令市場失望,但相信是適當反映市場情況,若果在2023財政年度Milwaukee業務增長約9%,在下半年並無進一步放緩,相信可以讓市場重拾信心。
該行因應創科上半年業績,將目標價由97元下調至91.5元,重申「買入」評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.